These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 32391993)

  • 1. [Male-female differences in the optimal dosage of medication for heart failure; the 'one-size-fits-all' approach to guidelines needs revision].
    Groenewegen A; Mosterd A; Rutten FH
    Ned Tijdschr Geneeskd; 2020 Mar; 164():. PubMed ID: 32391993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study.
    Santema BT; Ouwerkerk W; Tromp J; Sama IE; Ravera A; Regitz-Zagrosek V; Hillege H; Samani NJ; Zannad F; Dickstein K; Lang CC; Cleland JG; Ter Maaten JM; Metra M; Anker SD; van der Harst P; Ng LL; van der Meer P; van Veldhuisen DJ; Meyer S; Lam CSP; ; Voors AA
    Lancet; 2019 Oct; 394(10205):1254-1263. PubMed ID: 31447116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study.
    Teng TK; Tromp J; Tay WT; Anand I; Ouwerkerk W; Chopra V; Wander GS; Yap JJ; MacDonald MR; Xu CF; Chia YM; Shimizu W; ; Richards AM; Voors A; Lam CS
    Lancet Glob Health; 2018 Sep; 6(9):e1008-e1018. PubMed ID: 30103979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Higher versus lower doses of ACE inhibitors, angiotensin-2 receptor blockers and beta-blockers in heart failure with reduced ejection fraction: Systematic review and meta-analysis.
    Turgeon RD; Kolber MR; Loewen P; Ellis U; McCormack JP
    PLoS One; 2019; 14(2):e0212907. PubMed ID: 30817783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medical therapy doses at hospital discharge in patients with existing and de novo heart failure.
    Diamant MJ; Virani SA; MacKenzie WJ; Ignaszewski A; Toma M; Hawkins NM
    ESC Heart Fail; 2019 Aug; 6(4):774-783. PubMed ID: 31218850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nurse-Led Titration of Angiotensin-Converting Enzyme Inhibitors, β-Adrenergic Blocking Agents, and Angiotensin Receptor Blockers in Patients With Heart Failure With Reduced Ejection Fraction.
    Driscoll A; Currey J; Tonkin AM
    JAMA Cardiol; 2016 Oct; 1(7):842-843. PubMed ID: 27556747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomarker-Guided Versus Guideline-Based Treatment of Patients With Heart Failure: Results From BIOSTAT-CHF.
    Ouwerkerk W; Zwinderman AH; Ng LL; Demissei B; Hillege HL; Zannad F; van Veldhuisen DJ; Samani NJ; Ponikowski P; Metra M; Ter Maaten JM; Lang CC; van der Harst P; Filippatos G; Dickstein K; Cleland JG; Anker SD; Voors AA
    J Am Coll Cardiol; 2018 Jan; 71(4):386-398. PubMed ID: 29389354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics Associated with Upper-Range Doses of Beta-Blockers and Angiotensin-Renin Inhibitors in Reduced Ejection Fraction.
    Itzhaki Ben Zadok O; Murninkas D; Iakobishvili Z; Jino H; Yohananov E; Birkenfeld S; Hasdai D
    Isr Med Assoc J; 2020 Jul; 22(7):441-445. PubMed ID: 33236570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Higher medication doses in heart failure?
    McCormack J; McAlister FA; Kolber MR
    Can Fam Physician; 2017 Jan; 63(1):e20. PubMed ID: 28115456
    [No Abstract]   [Full Text] [Related]  

  • 10. Should we revise our approach to 'optimal medical therapy'? The case of chronic heart failure.
    Tavazzi L; Maggioni AP; Borer JS
    Eur Heart J; 2013 Sep; 34(36):2792-4. PubMed ID: 23892200
    [No Abstract]   [Full Text] [Related]  

  • 11. Target Doses of Heart Failure Medical Therapy and Blood Pressure: Insights From the CHAMP-HF Registry.
    Peri-Okonny PA; Mi X; Khariton Y; Patel KK; Thomas L; Fonarow GC; Sharma PP; Duffy CI; Albert NM; Butler J; Hernandez AF; McCague K; Williams FB; DeVore AD; Patterson JH; Spertus JA
    JACC Heart Fail; 2019 Apr; 7(4):350-358. PubMed ID: 30738978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in medical treatment and clinical characteristics between men and women with heart failure - a single-centre multivariable analysis.
    Norberg H; Pranic V; Bergdahl E; Lindmark K
    Eur J Clin Pharmacol; 2020 Apr; 76(4):539-546. PubMed ID: 31897534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nurse-coordinated collaborative disease management improves the quality of guideline-recommended heart failure therapy, patient-reported outcomes, and left ventricular remodelling.
    Güder G; Störk S; Gelbrich G; Brenner S; Deubner N; Morbach C; Wallenborn J; Berliner D; Ertl G; Angermann CE
    Eur J Heart Fail; 2015 Apr; 17(4):442-52. PubMed ID: 25727879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse Drug Reactions to Guideline-Recommended Heart Failure Drugs in Women: A Systematic Review of the Literature.
    Bots SH; Groepenhoff F; Eikendal ALM; Tannenbaum C; Rochon PA; Regitz-Zagrosek V; Miller VM; Day D; Asselbergs FW; den Ruijter HM
    JACC Heart Fail; 2019 Mar; 7(3):258-266. PubMed ID: 30819382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment with higher dosages of heart failure medication is associated with improved outcome following cardiac resynchronization therapy.
    Schmidt S; Hürlimann D; Starck CT; Hindricks G; Lüscher TF; Ruschitzka F; Steffel J
    Eur Heart J; 2014 Apr; 35(16):1051-60. PubMed ID: 24371079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adherence to Treatment Guidelines in Heart Failure Patients in the Top End Region of Northern Territory.
    Mu M; Majoni SW; Iyngkaran P; Haste M; Kangaharan N
    Heart Lung Circ; 2019 Jul; 28(7):1042-1049. PubMed ID: 29980453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Stepwise Approach to the Management of Heart Failure and its Comorbidities.
    Rogers FJ; Saghir Z
    J Am Osteopath Assoc; 2020 Feb; 120(2):90-99. PubMed ID: 31985768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of spironolactone in heart failure patients receiving angiotensin-converting enzyme inhibitors and beta-blockers.
    Ahmed A
    J Am Coll Cardiol; 2003 May; 41(10):1851-2. PubMed ID: 12767683
    [No Abstract]   [Full Text] [Related]  

  • 19. [Temporal trends in pharmacological therapy in the IN-CHF registry from 1995 to 2005].
    Fabbri G; Gorini M; Maggioni AP; Di Lenarda A;
    G Ital Cardiol (Rome); 2007 Feb; 8(2):102-6. PubMed ID: 17402354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ACP Journal Club. Review: In HF with reduced EF, nurse-led titration of HF drugs reduces hospitalizations and mortality.
    Shah T; Deswal A
    Ann Intern Med; 2016 Apr; 164(8):JC41. PubMed ID: 27089090
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.